Scott Hutton Appointed CEO of Biodesix

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

Current Chief Operating Officer Scott Hutton will become Chief Executive Officer of Biodesix on January 1, 2020. Current CEO David Brunel will assume the role of Chairman. Brunel is the co-founder of Biodesix and has led the company for more than 13 years. He will continue in a day-to-day advisory capacity assisting with strategic direction and key partnerships. Mr. Brunel and Mr. Hutton will continue to work together to ensure a smooth transition and to further the Biodesix mission to improve every patient’s lung cancer care by empowering physicians with swift, comprehensive, and actionable insights.

Hutton currently serves as Chief Operating Officer with more than 20 years of experience in the medical device, medical technology, and diagnostics industries. As COO, Hutton has been responsible for overseeing the corporate strategy, including the acquisition of Integrated Diagnostics and Oncimmune USA, execution of the commercial operations for the Biodesix portfolio of leading lung cancer diagnostics, and the launch of the Nodify XL2™ test to improve the assessment of incidental lung nodules. Prior to Biodesix, Hutton was the Sr. Vice President and General Manager, Vascular Interventions at Spectranetics, and Vice President and General Manager, Neurosurgery at Medtronic.

“Scott’s experience building and growing commercial organizations and proven leadership make him the ideal CEO to guide Biodesix into its next level of growth,” said Robert Cawthorn, co-founder and current Chairman of the Biodesix Board, who will remain on the Board following the transition. “The Board is grateful to David for his dedication, loyalty, and leadership in taking Biodesix from a concept to a company improving the lives of patients with lung cancer on a daily basis.”

“I’m proud and honored to be a part of this talented team working to achieve a worthy mission,” stated Hutton. “With our growing portfolio of genomic and proteomic blood tests steadily gaining recognition as valuable non-invasive options to help with more accurate diagnosis and treatment decisions, I believe the Biodesix team is poised to positively impact the lives of patients for many years to come. I look forward to continued collaboration with David and am eager to build upon the legacy that David created.”

“Biodesix is growing rapidly and this strategic change in our executive leadership reflects that growth as well as the substantial opportunities we have before us,” said Brunel. “Scott has been a tremendous asset to the company as our chief operating officer, he is perfectly suited to lead Biodesix’s continued commercial growth, research and development efforts, which have built, and continue to expand our deep product portfolio in lung cancer diagnostics. I look forward to continuing to work closely with Scott in our new roles, and want to thank our employees, physicians, and partners for their commitment, hard work, and dedication to improving lung cancer care.”

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.